Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.40 EUR
−20.35 M EUR
9.86 M EUR
8.99 M
About HEIDELBERG PHARMA AG
Sector
CEO
Andreas Pahl
Headquarters
Ladenburg
Website
Founded
1997
ISIN
DE000A11QVV0
FIGI
BBG000C1B2N1
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The firm focuses on oncology; and development Amanitin, a toxin used in cancer therapies. It also offers tumor implantation models, inflammatory and autoimmune diseases, and bioanalytics services. The company was founded by Olaf G. Wilhelm, Manfred Schmitt, Viktor Magdolen, Heinrich Graeff, Bernd Gänsbacher, Horst Kessler, Peter Nawroth, and Thomas Luther in September 1997 and is headquartered in Ladenburg, Germany.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HPHA is 2.11 EUR — it has decreased by −4.52% in the past 24 hours. Watch HEIDELBERG PHARMA AG O.N. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange HEIDELBERG PHARMA AG O.N. stocks are traded under the ticker HPHA.
HPHA stock has fallen by −10.97% compared to the previous week, the month change is a −18.85% fall, over the last year HEIDELBERG PHARMA AG O.N. has showed a −22.43% decrease.
We've gathered analysts' opinions on HEIDELBERG PHARMA AG O.N. future price: according to them, HPHA price has a max estimate of 11.30 EUR and a min estimate of 8.80 EUR. Watch HPHA chart and read a more detailed HEIDELBERG PHARMA AG O.N. stock forecast: see what analysts think of HEIDELBERG PHARMA AG O.N. and suggest that you do with its stocks.
HPHA reached its all-time high on Oct 1, 2008 with the price of 49.97 EUR, and its all-time low was 2.18 EUR and was reached on Nov 12, 2024. View more price dynamics on HPHA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HPHA stock is 4.74% volatile and has beta coefficient of 0.57. Track HEIDELBERG PHARMA AG O.N. stock price on the chart and check out the list of the most volatile stocks — is HEIDELBERG PHARMA AG O.N. there?
Today HEIDELBERG PHARMA AG O.N. has the market capitalization of 104.39 M, it has decreased by −4.27% over the last week.
Yes, you can track HEIDELBERG PHARMA AG O.N. financials in yearly and quarterly reports right on TradingView.
HEIDELBERG PHARMA AG O.N. is going to release the next earnings report on Jan 29, 2025. Keep track of upcoming events with our Earnings Calendar.
HPHA net income for the last quarter is −5.59 M EUR, while the quarter before that showed −4.17 M EUR of net income which accounts for −34.09% change. Track more HEIDELBERG PHARMA AG O.N. financial stats to get the full picture.
No, HPHA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 105.00 employees. See our rating of the largest employees — is HEIDELBERG PHARMA AG O.N. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HEIDELBERG PHARMA AG O.N. EBITDA is −20.33 M EUR, and current EBITDA margin is −270.21%. See more stats in HEIDELBERG PHARMA AG O.N. financial statements.
Like other stocks, HPHA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HEIDELBERG PHARMA AG O.N. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HEIDELBERG PHARMA AG O.N. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HEIDELBERG PHARMA AG O.N. stock shows the sell signal. See more of HEIDELBERG PHARMA AG O.N. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.